In this study, through a combined transcriptomic and nontargeted metabolomic approach, we found that the initial differential effects of REV1 on lung cancer radiosensitivity in vitro and in vivo were caused by differences in the metabolic microenvironment. Here, REV1 is linked to lung cancer.